309 related articles for article (PubMed ID: 34399795)
1. Deep learning-based predictive biomarker of pathological complete response to neoadjuvant chemotherapy from histological images in breast cancer.
Li F; Yang Y; Wei Y; He P; Chen J; Zheng Z; Bu H
J Transl Med; 2021 Aug; 19(1):348. PubMed ID: 34399795
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the Predictive and Prognostic Values of Stromal Tumor-Infiltrating Lymphocytes in HER2-Positive Breast Cancers treated with neoadjuvant chemotherapy.
Yang X; Rao J; Yang W; Shui R
Target Oncol; 2018 Dec; 13(6):757-767. PubMed ID: 30406444
[TBL] [Abstract][Full Text] [Related]
3. Impact of stromal tumor-infiltrating lymphocytes (sTILs) on response to neoadjuvant chemotherapy in triple-negative early breast cancer in the WSG-ADAPT TN trial.
Kolberg-Liedtke C; Feuerhake F; Garke M; Christgen M; Kates R; Grischke EM; Forstbauer H; Braun M; Warm M; Hackmann J; Uleer C; Aktas B; Schumacher C; Kuemmel S; Wuerstlein R; Graeser M; Nitz U; Kreipe H; Gluz O; Harbeck N
Breast Cancer Res; 2022 Sep; 24(1):58. PubMed ID: 36056374
[TBL] [Abstract][Full Text] [Related]
4. Deep learning with biopsy whole slide images for pretreatment prediction of pathological complete response to neoadjuvant chemotherapy in breast cancer：A multicenter study.
Li B; Li F; Liu Z; Xu F; Ye G; Li W; Zhang Y; Zhu T; Shao L; Chen C; Sun C; Qiu B; Bu H; Wang K; Tian J
Breast; 2022 Dec; 66():183-190. PubMed ID: 36308926
[TBL] [Abstract][Full Text] [Related]
5. Prediction of pathological complete response to neoadjuvant chemotherapy in breast cancer using a deep learning (DL) method.
Qu YH; Zhu HT; Cao K; Li XT; Ye M; Sun YS
Thorac Cancer; 2020 Mar; 11(3):651-658. PubMed ID: 31944571
[TBL] [Abstract][Full Text] [Related]
6. Predictive value of tumor-infiltrating lymphocytes to pathological complete response in neoadjuvant treated triple-negative breast cancers.
Ruan M; Tian T; Rao J; Xu X; Yu B; Yang W; Shui R
Diagn Pathol; 2018 Aug; 13(1):66. PubMed ID: 30170605
[TBL] [Abstract][Full Text] [Related]
7. A hierarchical self-attention-guided deep learning framework to predict breast cancer response to chemotherapy using pre-treatment tumor biopsies.
Saednia K; Tran WT; Sadeghi-Naini A
Med Phys; 2023 Dec; 50(12):7852-7864. PubMed ID: 37403567
[TBL] [Abstract][Full Text] [Related]
8. PROACTING: predicting pathological complete response to neoadjuvant chemotherapy in breast cancer from routine diagnostic histopathology biopsies with deep learning.
Aswolinskiy W; Munari E; Horlings HM; Mulder L; Bogina G; Sanders J; Liu YH; van den Belt-Dusebout AW; Tessier L; Balkenhol M; Stegeman M; Hoven J; Wesseling J; van der Laak J; Lips EH; Ciompi F
Breast Cancer Res; 2023 Nov; 25(1):142. PubMed ID: 37957667
[TBL] [Abstract][Full Text] [Related]
9. The importance of stromal and intratumoral tumor lymphocyte infiltration for pathologic complete response in patients with locally advanced breast cancer.
Eryilmaz MK; Mutlu H; Ünal B; Salim DK; Musri FY; Coşkun HŞ
J Cancer Res Ther; 2018; 14(3):619-624. PubMed ID: 29893329
[TBL] [Abstract][Full Text] [Related]
10. Digital histopathological images of biopsy predict response to neoadjuvant chemotherapy for locally advanced gastric cancer.
Zhou Z; Ren Y; Zhang Z; Guan T; Wang Z; Chen W; Luo T; Li G
Gastric Cancer; 2023 Sep; 26(5):734-742. PubMed ID: 37322381
[TBL] [Abstract][Full Text] [Related]
11. Predicting Neoadjuvant Treatment Response in Triple-Negative Breast Cancer Using Machine Learning.
Bhattarai S; Saini G; Li H; Seth G; Fisher TB; Janssen EAM; Kiraz U; Kong J; Aneja R
Diagnostics (Basel); 2023 Dec; 14(1):. PubMed ID: 38201383
[TBL] [Abstract][Full Text] [Related]
12. Predictive markers for pathological complete response after neo-adjuvant chemotherapy in triple-negative breast cancer.
Van Bockstal MR; Noel F; Guiot Y; Duhoux FP; Mazzeo F; Van Marcke C; Fellah L; Ledoux B; Berlière M; Galant C
Ann Diagn Pathol; 2020 Dec; 49():151634. PubMed ID: 32987254
[TBL] [Abstract][Full Text] [Related]
13. Digital image analysis and machine learning-assisted prediction of neoadjuvant chemotherapy response in triple-negative breast cancer.
Fisher TB; Saini G; Rekha TS; Krishnamurthy J; Bhattarai S; Callagy G; Webber M; Janssen EAM; Kong J; Aneja R
Breast Cancer Res; 2024 Jan; 26(1):12. PubMed ID: 38238771
[TBL] [Abstract][Full Text] [Related]
14. Combining the tumor-stroma ratio with tumor-infiltrating lymphocytes improves the prediction of pathological complete response in breast cancer patients.
Li F; Chen H; Lu X; Wei Y; Zhao Y; Fu J; Xiao X; Bu H
Breast Cancer Res Treat; 2023 Nov; 202(1):173-183. PubMed ID: 37528265
[TBL] [Abstract][Full Text] [Related]
15. Optimal threshold for stromal tumor-infiltrating lymphocytes: its predictive and prognostic value in HER2-positive breast cancer treated with trastuzumab-based neoadjuvant chemotherapy.
Liu S; Duan X; Xu L; Xin L; Cheng Y; Liu Q; Ye J; Zhang S; Zhang H; Zhu S; Li T; Liu Y
Breast Cancer Res Treat; 2015 Nov; 154(2):239-49. PubMed ID: 26498019
[TBL] [Abstract][Full Text] [Related]
16. Predicting neoadjuvant treatment response in triple-negative breast cancer using machine learning.
Bhattarai S; Saini G; Li H; Duanmu H; Seth G; Fisher TB; Janssen EAM; Kiraz U; Kong J; Aneja R
bioRxiv; 2023 Apr; ():. PubMed ID: 37131688
[TBL] [Abstract][Full Text] [Related]
17. Prediction of Treatment Response to Neoadjuvant Chemotherapy in Breast Cancer by Subtype Using Tumor-infiltrating Lymphocytes.
Asano Y; Kashiwagi S; Goto W; Takada K; Takahashi K; Hatano T; Takashima T; Tomita S; Motomura H; Ohsawa M; Hirakawa K; Ohira M
Anticancer Res; 2018 Apr; 38(4):2311-2321. PubMed ID: 29599354
[TBL] [Abstract][Full Text] [Related]
18. Deep learning-based predictive model for pathological complete response to neoadjuvant chemotherapy in breast cancer from biopsy pathological images: a multicenter study.
Zeng H; Qiu S; Zhuang S; Wei X; Wu J; Zhang R; Chen K; Wu Z; Zhuang Z
Front Physiol; 2024; 15():1279982. PubMed ID: 38357498
[No Abstract] [Full Text] [Related]
19. Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer.
Perez EA; Ballman KV; Tenner KS; Thompson EA; Badve SS; Bailey H; Baehner FL
JAMA Oncol; 2016 Jan; 2(1):56-64. PubMed ID: 26469139
[TBL] [Abstract][Full Text] [Related]
20. Tumor-Infiltrating Lymphocytes Improve Magee Equation-Based Prediction of Pathologic Complete Response in HR-Positive/HER2-Negative Breast Cancer.
Li F; Zhao Y; Wei Y; Xi Y; Bu H
Am J Clin Pathol; 2022 Aug; 158(2):291-299. PubMed ID: 35486808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
